Cargando…
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
The prognosis of adult soft tissue sarcoma (STS) patients with metastases is generally poor. As little is known about the impact of the involvement of different metastatic sites and the extent of pulmonary lesions on the outcome for patients receiving first‐line chemotherapy, we aimed to establish p...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947111/ https://www.ncbi.nlm.nih.gov/pubmed/29383713 http://dx.doi.org/10.1002/ijc.31286 |
_version_ | 1783322305528594432 |
---|---|
author | Lindner, Lars H. Litière, Saskia Sleijfer, Stefan Benson, Charlotte Italiano, Antoine Kasper, Bernd Messiou, Christina Gelderblom, Hans Wardelmann, Eva Le Cesne, Axel Blay, Jean‐Yves Marreaud, Sandrine Hindi, Nadia Desar, Ingrid M.E. Gronchi, Alessandro van der Graaf, Winette T.A. |
author_facet | Lindner, Lars H. Litière, Saskia Sleijfer, Stefan Benson, Charlotte Italiano, Antoine Kasper, Bernd Messiou, Christina Gelderblom, Hans Wardelmann, Eva Le Cesne, Axel Blay, Jean‐Yves Marreaud, Sandrine Hindi, Nadia Desar, Ingrid M.E. Gronchi, Alessandro van der Graaf, Winette T.A. |
author_sort | Lindner, Lars H. |
collection | PubMed |
description | The prognosis of adult soft tissue sarcoma (STS) patients with metastases is generally poor. As little is known about the impact of the involvement of different metastatic sites and the extent of pulmonary lesions on the outcome for patients receiving first‐line chemotherapy, we aimed to establish prognostic factors for STS patients with lung metastases only. A retrospective, exploratory analysis was performed on 2,913 metastatic STS patients who received first‐line chemotherapy. Detailed information from 580 patients who had lung metastases only, was used for prognostic factor analysis. Patients with lung metastases only were more often asymptomatic and had undergone complete primary tumor resection more frequently compared to patients with additional metastases outside the lung or without lung metastases. For extremity STS, the incidence of lung metastases only was much higher compared to non‐extremity STS. Lung involvement only was an independent favorable prognostic factor for overall survival (OS) with regard to metastatic site. Within this subgroup, in a multivariate model, other factors associated with improved OS included: good performance status (PS), no progression at primary site, low histological grade, younger age, long interval between initial diagnosis and trial registration, and smaller diameter of the largest lung lesion. This unique analysis on prognostic factors in STS patients with lung metastases confirms well‐known patient factors (such as age and PS), and tumor characteristics (including tumor grade, interval between primary diagnosis, and metastases), but also identifies diameter of the largest lung lesion as a new prognostic factor. Knowledge about these factors may support decision‐making within multidisciplinary tumor boards. |
format | Online Article Text |
id | pubmed-5947111 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59471112018-05-17 Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) Lindner, Lars H. Litière, Saskia Sleijfer, Stefan Benson, Charlotte Italiano, Antoine Kasper, Bernd Messiou, Christina Gelderblom, Hans Wardelmann, Eva Le Cesne, Axel Blay, Jean‐Yves Marreaud, Sandrine Hindi, Nadia Desar, Ingrid M.E. Gronchi, Alessandro van der Graaf, Winette T.A. Int J Cancer Cancer Therapy and Prevention The prognosis of adult soft tissue sarcoma (STS) patients with metastases is generally poor. As little is known about the impact of the involvement of different metastatic sites and the extent of pulmonary lesions on the outcome for patients receiving first‐line chemotherapy, we aimed to establish prognostic factors for STS patients with lung metastases only. A retrospective, exploratory analysis was performed on 2,913 metastatic STS patients who received first‐line chemotherapy. Detailed information from 580 patients who had lung metastases only, was used for prognostic factor analysis. Patients with lung metastases only were more often asymptomatic and had undergone complete primary tumor resection more frequently compared to patients with additional metastases outside the lung or without lung metastases. For extremity STS, the incidence of lung metastases only was much higher compared to non‐extremity STS. Lung involvement only was an independent favorable prognostic factor for overall survival (OS) with regard to metastatic site. Within this subgroup, in a multivariate model, other factors associated with improved OS included: good performance status (PS), no progression at primary site, low histological grade, younger age, long interval between initial diagnosis and trial registration, and smaller diameter of the largest lung lesion. This unique analysis on prognostic factors in STS patients with lung metastases confirms well‐known patient factors (such as age and PS), and tumor characteristics (including tumor grade, interval between primary diagnosis, and metastases), but also identifies diameter of the largest lung lesion as a new prognostic factor. Knowledge about these factors may support decision‐making within multidisciplinary tumor boards. John Wiley and Sons Inc. 2018-02-14 2018-06-15 /pmc/articles/PMC5947111/ /pubmed/29383713 http://dx.doi.org/10.1002/ijc.31286 Text en © 2018 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Therapy and Prevention Lindner, Lars H. Litière, Saskia Sleijfer, Stefan Benson, Charlotte Italiano, Antoine Kasper, Bernd Messiou, Christina Gelderblom, Hans Wardelmann, Eva Le Cesne, Axel Blay, Jean‐Yves Marreaud, Sandrine Hindi, Nadia Desar, Ingrid M.E. Gronchi, Alessandro van der Graaf, Winette T.A. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) |
title | Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) |
title_full | Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) |
title_fullStr | Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) |
title_full_unstemmed | Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) |
title_short | Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) |
title_sort | prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: an exploratory, retrospective analysis of the european organization for research and treatment of cancer‐soft tissue and bone sarcoma group (eortc‐stbsg) |
topic | Cancer Therapy and Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947111/ https://www.ncbi.nlm.nih.gov/pubmed/29383713 http://dx.doi.org/10.1002/ijc.31286 |
work_keys_str_mv | AT lindnerlarsh prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT litieresaskia prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT sleijferstefan prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT bensoncharlotte prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT italianoantoine prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT kasperbernd prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT messiouchristina prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT gelderblomhans prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT wardelmanneva prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT lecesneaxel prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT blayjeanyves prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT marreaudsandrine prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT hindinadia prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT desaringridme prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT gronchialessandro prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg AT vandergraafwinetteta prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg |